肺癌 CT 筛查：我们是否准备好在欧洲实施？

CT screening for lung cancer: Are we ready to implement in Europe?

机构信息

Manchester Thoracic Oncology Centre (MTOC), North West Lung Centre, Manchester University NHS Foundation Trust, Southmoor Road, Wythenshawe, UK; Division of Infection, Immunity and Respiratory Medicine, School of Biological Sciences, Faculty of Biology, Medicine and Health University of Manchester, Manchester, UK.

Manchester Thoracic Oncology Centre (MTOC), North West Lung Centre, Manchester University NHS Foundation Trust, Southmoor Road, Wythenshawe, UK.

出版信息

Lung Cancer. 2019 Aug;134:25-33. doi: 10.1016/j.lungcan.2019.05.028. Epub 2019 May 28.

DOI:10.1016/j.lungcan.2019.05.028

PMID:31319989

Abstract

Lung cancer screening with low-dose CT (LDCT) is already available in certain parts of the world, such as the United States, but not yet in Europe. The recently published European position statement on lung cancer screening has recommended planning for implementation of screening to start within 18-months [1]. Pilot European programmes are already underway, primarily in the United Kingdom (UK), delivering lung cancer screening to their local populations. This review article acknowledges the evidence base for LDCT screening and will discuss the challenges that still need to be overcome in an attempt to answer the question: are we ready to implement in Europe?

摘要

肺癌筛查使用低剂量 CT（LDCT）已经在世界某些地区（如美国）普及，但在欧洲还没有。最近发表的欧洲肺癌筛查立场声明建议在 18 个月内开始规划实施筛查[1]。试点性的欧洲计划已经启动，主要在英国（UK），为当地居民提供肺癌筛查。这篇综述文章承认了 LDCT 筛查的证据基础，并将讨论在尝试回答这个问题时仍需克服的挑战：我们是否已经准备好在欧洲实施？